Home
News
Create
Screeners
Insights
3B BlackBio DX
1,327.
50
+3.15
(+0.24%)
Market Cap
₹1,140.80 Cr
PE Ratio
23.26
Industry
Healthcare Services
Buy
Sell
Company Performance:
1D
+0.24%
1M
-4.53%
6M
-24.10%
1Y
-7.84%
5Y
+50.20%
View Company Insights
Latest news about 3B BlackBio DX
3B BlackBio Dx Reports 18% Revenue Growth in Q1 FY26, Acquires Belgium-Based Coris Bioconcept
Aug 23, 2025
3B BlackBio Dx Limited, a leading Indian molecular diagnostics company, reported an 18% year-on-year increase in Q1 FY26 sales to ₹19.96 crores, with EBITDA growing 11% to ₹16.19 crores. The company acquired Coris Bioconcept, a Belgian rapid diagnostics firm, for up to £4.77 million to expand its European presence. 3B BlackBio Dx holds a 12-15% market share in India and projects 15-20% growth for FY26, outpacing industry expectations. The company aims to increase export contribution from 17-18% to 35-40% of total revenue within five years. EBITDA margins are around 60% but expected to trend towards 55% due to competition. Current capacity utilization is at 65% with no major capital expenditure needed for 2-3 years.
3B BlackBio Dx Limited Reports Strong Q1 Results, Approves Key Board Appointments
Aug 14, 2025
3B BLACKBIO DX Reports Q4 Results: Revenue Up, EBITDA Down, Final Dividend Recommended
May 28, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation